SEC Form 4 · accession 0000899243-17-024268

SCICLONE PHARMACEUTICALS INC · SCLN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Friedhelm Blobel

Officer — President, CEO, Director · Director

Period of report

Oct 13, 2017

Accepted (ET)

Oct 16, 2017 · 5:17 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000880771

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Oct 13, 2017	M	95,000	—	A	237,299	D
Common Stock^F3	Oct 13, 2017	A	150,000	$0.00	A	387,299	D
Common Stock	Oct 13, 2017	D	387,299	$11.18	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Non-Qualified Stock Option (right to buy)^F4,F6,F5	$5.13	Oct 13, 2017	D	142,610	D	—	May 12, 2021	Common Stock	142,610	D
Non-Qualified Stock Option (right to buy)^F4,F6,F7	$6.22	Oct 13, 2017	D	200,000	D	—	Mar 15, 2022	Common Stock	200,000	D
Non-Qualified Stock Option (right to buy)^F4,F6,F8	$4.53	Oct 13, 2017	D	200,000	D	—	Apr 4, 2023	Common Stock	200,000	D
Non-Qualified Stock Option (right to buy)^F4,F6,F9	$4.52	Oct 13, 2017	D	200,000	D	—	Mar 14, 2024	Common Stock	200,000	D
Incentive Stock Option (right to buy)^F4,F6,F10	$8.83	Oct 13, 2017	D	42,725	D	—	Mar 16, 2025	Common Stock	42,725	D
Restricted Stock Unit^F4,F1,F11	—	Oct 13, 2017	M	10,000	D	—	—	Common Stock	10,000	D
Non-Qualified Stock Option (right to buy)^F4,F6,F10	$8.83	Oct 13, 2017	D	97,275	D	—	Mar 16, 2025	Common Stock	97,275	D
Restricted Stock Unit^F4,F1,F11	—	Oct 13, 2017	M	50,000	D	—	—	Common Stock	50,000	D
Incentive Stock Option (right to buy)^F12,F6,F13	$9.12	Oct 13, 2017	D	11,243	D	—	Mar 15, 2026	Common Stock	11,243	D
Non-Qualified Stock Option (right to buy)^F12,F6,F13	$9.12	Oct 13, 2017	D	128,757	D	—	Mar 15, 2026	Common Stock	128,757	D
Restricted Stock Unit^F12,F1,F11	—	Oct 13, 2017	M	15,000	D	—	—	Common Stock	15,000	D
Incentive Stock Option (right to buy)^F12,F6,F14	$9.65	Oct 13, 2017	D	10,843	D	—	Mar 8, 2027	Common Stock	10,843	D
Non-Qualified Stock Option (right to buy)^F12,F6,F14	$9.65	Oct 13, 2017	D	129,157	D	—	Mar 8, 2027	Common Stock	129,157	D
Restricted Stock Unit^F12,F1,F11	—	Oct 13, 2017	M	20,000	D	—	—	Common Stock	20,000	D

Explanation of responses

F1Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
F10Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
F11Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
F12Granted under Issuer's 2015 Equity Incentive Plan.
F13Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
F14Under its terms the option became exercisable in installments with 25% to vest on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
F2Includes 216 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on October 6, 2017 and 746 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on August 31, 2017.
F3Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities.
F4Granted under Issuer's 2005 Equity Incentive Plan.
F5Under its terms the option became exercisable in installments with 25% vesting on April 5, 2012 and 2.0833% vesting each month thereafter until it became vested in full on April 5, 2015.
F6The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
F7Under its terms the option became exercisable in installments with 25% vesting on March 15, 2013 and 2.0833% vesting each month thereafter until it became vested in full on March 15, 2016.
F8Under its terms the option became exercisable in installments with 25% vesting on April 4, 2014 and 2.0833% vesting each month thereafter until it became vested in full on April 4, 2017.
F9Under its terms the option became exercisable in installments with 25% vesting on March 14, 2015 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.